Clearside Biomedical Ownership
| CLSD Stock | USD 0.95 0.02 2.15% |
Shares in Circulation | First Issued 2015-03-31 | Previous Quarter 75 M | Current Value 75 M | Avarage Shares Outstanding 39.7 M | Quarterly Volatility 22.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Clearside |
Clearside Stock Ownership Analysis
About 23.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings (P/E) ratio of 130.0. Clearside Biomedical recorded a loss per share of 0.45. The entity had not issued any dividends in recent years. Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. Clearside Biomedi operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people. For more info on Clearside Biomedical please contact JD PharmD at 678 270 3631 or go to https://clearsidebio.com.Besides selling stocks to institutional investors, Clearside Biomedical also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Clearside Biomedical's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Clearside Biomedical's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Clearside Biomedical Quarterly Liabilities And Stockholders Equity |
|
About 7.0% of Clearside Biomedical are currently held by insiders. Unlike Clearside Biomedical's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Clearside Biomedical's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Clearside Biomedical's insider trades
Clearside Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Clearside Biomedical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Clearside Biomedical backward and forwards among themselves. Clearside Biomedical's institutional investor refers to the entity that pools money to purchase Clearside Biomedical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 130.2 K | Rosalind Advisors, Inc. | 2024-09-30 | 127.2 K | Pnc Financial Services Group Inc | 2024-09-30 | 107.9 K | Brown Wealth Management, Llc | 2024-09-30 | 100 K | Northeast Financial Consultants, Inc | 2024-09-30 | 93 K | Captrust Financial Advisors | 2024-09-30 | 92.7 K | Millennium Management Llc | 2024-09-30 | 91 K | Johnson & Johnson | 2024-09-30 | 82.5 K | Citadel Advisors Llc | 2024-09-30 | 71.6 K | Vanguard Group Inc | 2024-09-30 | 2.8 M | Carmignac Gestion | 2024-09-30 | 1.9 M |
Clearside Biomedical Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Clearside Biomedical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Clearside Biomedical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Clearside Biomedical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Clearside Biomedical Outstanding Bonds
Clearside Biomedical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Clearside Biomedical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Clearside bonds can be classified according to their maturity, which is the date when Clearside Biomedical has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Clearside Biomedical is a strong investment it is important to analyze Clearside Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearside Biomedical's future performance. For an informed investment choice regarding Clearside Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearside Biomedical. If investors know Clearside will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearside Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Revenue Per Share | Quarterly Revenue Growth (0.91) | Return On Assets | Return On Equity |
The market value of Clearside Biomedical is measured differently than its book value, which is the value of Clearside that is recorded on the company's balance sheet. Investors also form their own opinion of Clearside Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Clearside Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearside Biomedical's market value can be influenced by many factors that don't directly affect Clearside Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearside Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearside Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearside Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.